Table 1 Patients’characteristics – patients with no prior treatment (n = 32)
Characteristic | n (%) |
|---|---|
Tumor stage | |
cT1c | 6 (18.8) |
cT2a | 1 (3.1) |
cT2b | 3 (9.4) |
cT2c | 4 (12.5) |
cT3a | 5 (15.6) |
cT3b | 3 (9.4) |
Tx | 6 (18.8) |
cN1 | 32 (100) |
cM0 | 30 (93.75) |
cM1a | 1 (3.1) |
cM1b | 0 |
D’Amico risk group | |
Low | 2 (6.3) |
Intermediate | 4 (12.5) |
High | 26 (81.25) |
Initial PSA level (ng/ml) | |
Mean | 32.78 |
Median | 21.71 |
Range | 5.1–198.0 |
PSA at the time of PET/CT (ng/ml) | |
Mean | 22.7 |
Median | 12.5 |
Range | 0.03–99.0 |
Gleason score | |
≤6 | 7 (21.88) |
7 (3 + 4) | 3 (9.4) |
7 (4 + 3) | 4 (12.5) |
8 | 1 (3.1) |
9 | 8 (25.0) |
missing | 9 (28.1) |
Age (years) | |
Mean | 69.2 |
Median | 71 |
Range | 51–80 |
Time from initial diagnosis until PET/CT (months) | |
Mean | 10.8 |
Median | 1 |
Range | 0–83 |